Dr Joseph McCollom DO (@realbowtiedoc) 's Twitter Profile
Dr Joseph McCollom DO

@realbowtiedoc

#FosterCare alum #GIonc #pallonc #survonc @ParkviewHealth #supponc Co-Chair: @PallOncCoP #OncoAlertAF🚨 #SoMe Editor @OncJournal COI: shorturl.at/bcwU5

ID: 1170440187001933824

calendar_today07-09-2019 20:54:29

9,9K Tweet

3,3K Followers

2,2K Following

Yakup Ergün (@dr_yakupergun) 's Twitter Profile Photo

Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis 💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS ❗️An analysis based on MSI status and T4a/b was not performed

Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis 

💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS 

❗️An analysis based on MSI status and T4a/b was not performed
Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

~1 week to #ESMO24, here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC! - #NIAGARA - #KN522 - #NATALEE - #DB12 - #MARIPOSA2 - #KRYSTAL12 - #NICHE2 - #SAKK41 - #POD1UM - #KN811 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter ESMO - Eur. Oncology OncoAlert

~1 week to #ESMO24, here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC!

- #NIAGARA
- #KN522
- #NATALEE
- #DB12
- #MARIPOSA2
- #KRYSTAL12
- #NICHE2
- #SAKK41 
- #POD1UM 
- #KN811  

#BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/OncoAlert/">OncoAlert</a>
Erman Akkus (@erman_akkus) 's Twitter Profile Photo

🧬Mismatch repair in pancreatic cancer JAMA Oncology ✅Although it is rare, MSI should be tested in pancreatic cancer ✅Median IO duration: 27.7 months, DCR: 80% 👉doi:10.1001/jamaoncol.2024.3651 Catherine O’Connor Emily Harrold Wungki Park, MD MS Eileen M O’Reilly #cancer #Oncology #MedX

🧬Mismatch repair in pancreatic cancer
<a href="/JAMAOnc/">JAMA Oncology</a> 

✅Although it is rare, MSI should be tested in pancreatic cancer
✅Median IO duration: 27.7 months, DCR: 80%

👉doi:10.1001/jamaoncol.2024.3651

<a href="/CatherineaOC/">Catherine O’Connor</a> <a href="/EmilyHarrold6/">Emily Harrold</a> <a href="/CentralParkWMD/">Wungki Park, MD MS</a> <a href="/EileenMOReilly/">Eileen M O’Reilly</a> #cancer #Oncology #MedX
Darcy Burbage, DNP, RN, AOCN (@darcyburbage) 's Twitter Profile Photo

Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records ⁦Journal of Clinical Oncology⁩ ⁦OncoAlert⁩ ascopubs.org/doi/10.1200/JC…

Myriam Chalabi (@myriamchalabi) 's Twitter Profile Photo

Two years later, on Sept 15th #ESMO24, I will present the long awaited 3-year DFS data for NICHE-2 ‼️ But that’s not all…exciting🩸ctDNA dynamics included. See you there! ESMO - Eur. Oncology The Netherlands Cancer Institute

Dr Joseph McCollom DO (@realbowtiedoc) 's Twitter Profile Photo

The engaging Billy Rosa, PhD, MBE, APRN and colleagues discuss #equity in ASCO guidelines for JCO Oncology Practice: • 🗣️Name needs 🚫 exclusion • 🌈No consensus if no #diversity • ⚡️How to share about #bias • 🎙️Everyone needs a voice ascopubs.org/doi/pdf/10.120… ASCO PallOnc Community of Practice OncoAlert🚨

OncoAlert (@oncoalert) 's Twitter Profile Photo

The OncoAlert 🚨Newsletter NOW OUT Covering August 30- Sept5, 2024 Register at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅TROPHY-U-01 #BladderCancer ✅DeLLphi-300🫁 SC #LungCancer ✅LITESPARK-013 #KidneyCancer ✅RADICALS-HD☢️ #ProstateCancer

Dr Joseph McCollom DO (@realbowtiedoc) 's Twitter Profile Photo

📜Extra! Extra! 📜 #survonc The importance of 💝#CardioOnc 💝in long term care. ✨Excellent patient resource✨ Eric K. Singhi, MD #GIonc - Review of innovations in #hpbcsm including #IO + 💉#chemo combos, new 🎯 and #biomarkers 🧬 Sign up: Oncoalert360.com

OncoAlert (@oncoalert) 's Twitter Profile Photo

Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study out on The Lancet Oncology thelancet.com/journals/lanon… This phase 3 randomized controlled trial (CCTG HE1) aimed to

Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study out on <a href="/TheLancetOncol/">The Lancet Oncology</a> 

thelancet.com/journals/lanon…

This phase 3 randomized controlled trial (CCTG HE1) aimed to